Ripamonti C I, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E
Palliative Care Unit (Pain Therapy and Rehabilitation), IRCCS Foundation, National Cancer Institute of Milan, Milan, Italy.
Ann Oncol. 2009 Jan;20(1):137-45. doi: 10.1093/annonc/mdn526. Epub 2008 Jul 22.
Screening of the oral cavity and dental care was suggested as mandatory preventive measures of osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BPs). We investigated the occurrence of ONJ before and after implementation of dental preventive measures when starting BP therapy.
Since April 2005, 154 consecutive patients treated with BPs (POST-Group) have undergone a baseline mouth assessment (dental visit +/- orthopantomography of the jaws) to detect potential dental conditions and dental care if required. A retrospective review was also conducted of all consecutive cancer patients with bone metastases (PRE-Group) and treated for the first time with BPs from January 1999 to April 2005 in our clinic without receiving any preventive measure. Incidence proportion and incidence rate (IR) were used to estimate the incidence of ONJ.
Among the study population (966 patients; male/female=179/787), 73% had breast cancer. 25% of patients were given zoledronic acid (ZOL), 62% pamidronate (PAM), 8% PAM followed by ZOL and 5% clodronate. ONJ was observed in 28 patients (2.9%); we observed a reduction in the incidence of ONJ from 3.2% to 1.3%, when comparing-pre and post-implementation of preventive measures programme. Considering the patients exposed to ZOL, the performance of a dental examination and the application of preventive measures led to a sustained reduction in ONJ IR (7.8% in the PRE-Group versus 1.7% in the POST-Group; P=0.016), with an IR ratio of 0.30 (95% confidence interval 0.03-1.26).
ONJ is a manageable and preventable condition. Our data confirm that the application of preventive measures can significantly reduce the incidence of ONJ in cancer patients receiving BPs therapy. Dental exams combined to the identification of patients at risk in cooperation with the Dental Team can improve outcomes and increase the number of ONJ-free patients.
口腔筛查和牙齿护理被建议作为接受双膦酸盐(BP)治疗患者颌骨坏死(ONJ)的强制性预防措施。我们调查了开始BP治疗时实施牙齿预防措施前后ONJ的发生情况。
自2005年4月起,154例连续接受BP治疗的患者(POST组)接受了基线口腔评估(牙科检查+/-颌骨全景X线片),以检测潜在的牙齿状况,并在需要时进行牙齿护理。我们还对1999年1月至2005年4月在我们诊所首次接受BP治疗且未接受任何预防措施的所有连续骨转移癌患者(PRE组)进行了回顾性研究。发病率比例和发病率(IR)用于估计ONJ的发生率。
在研究人群(966例患者;男/女=179/787)中,73%患有乳腺癌。25%的患者使用唑来膦酸(ZOL),62%使用帕米膦酸(PAM),8%先使用PAM后使用ZOL,5%使用氯膦酸。28例患者(2.9%)发生ONJ;比较预防措施方案实施前后,我们观察到ONJ的发生率从3.2%降至1.3%。考虑到使用ZOL的患者,进行牙科检查和应用预防措施导致ONJ的IR持续降低(PRE组为7.8%,POST组为1.7%;P=0.016),IR比值为0.30(95%置信区间0.03-1.26)。
ONJ是一种可控制和可预防的病症。我们的数据证实,应用预防措施可显著降低接受BP治疗的癌症患者ONJ的发生率。牙科检查与牙科团队合作识别高危患者相结合,可改善治疗效果并增加无ONJ患者的数量。